StemCell Therapy

UNITY Biotechnology, a privately held biotechnology company creating therapeutics that prevent, halt, or reverse numerous diseases of aging, announced the closing of an additional$35 millionin Series B financing. This second close of the Series B, in addition to the initial close infall of 2016, brings the total amount of this financing to$151 million.

The UNITY Series B financing ranks among the largest private financings in biotech history. New Series B investors include INVUS Opportunities, Three Lakes Partners, Cycad Group, COM Investments, and Pivotal Alpha Limited.These new investors join the Series B led by longtime life science investors ARCH Venture Partners, Baillie Gifford, Fidelity Management and Research Company, Partner Fund Management, and Venrock. Other investors include Bezos Expeditions, Vulcan Capital, Founders Fund, WuXi PharmaTech, and Mayo Clinic Ventures. Proceeds from this financing will be used to expand ongoing research programs in cellular senescence and advance the first preclinical programs into human trials.

UNITYalsoannounced thatGraham Cooperhas joined UNITY's board of directors. Mr. Cooper was previously the chief financial officer ofReceptos,which was acquired by Celgene in 2015 for$7.8 billion.

"We are incredibly fortunate to have attracted someone of Graham's experience and judgment to help us shape our mission of attacking diseases of aging and fundamentally reshaping human healthspan," saidKeith Leonard, UNITY chairman and CEO. "The incredible investor support matched with the progress in preclinical development has us on track to initiate clinical trials in 2018 with our first senolytic drug."

"UNITY pairs a huge market opportunity with highly compelling biology and a proven and experienced management team. We continue to attract both a highly skilled team and deep financial backing to match the potential," saidRobert Nelsen, UNITY board member and co-founder and managing director of ARCH Venture Partners, UNITY's founding investor.

Go here to read the rest:
UNITY Biotechnology Announces Series B Financing Extension ... - Drug Discovery & Development

This entry was posted on August 22, 2017 at 7:44 pm and is filed under Biotechnology. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |